235 related articles for article (PubMed ID: 30015382)
1. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
3. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
6. Modeling a lethal prostate cancer variant with small-cell carcinoma features.
Tzelepi V; Zhang J; Lu JF; Kleb B; Wu G; Wan X; Hoang A; Efstathiou E; Sircar K; Navone NM; Troncoso P; Liang S; Logothetis CJ; Maity SN; Aparicio AM
Clin Cancer Res; 2012 Feb; 18(3):666-77. PubMed ID: 22156612
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Malihi PD; Graf RP; Rodriguez A; Ramesh N; Lee J; Sutton R; Jiles R; Ruiz Velasco C; Sei E; Kolatkar A; Logothetis C; Navin NE; Corn P; Aparicio AM; Dittamore R; Hicks J; Kuhn P; Zurita AJ
Clin Cancer Res; 2020 Aug; 26(15):4143-4153. PubMed ID: 32341031
[TBL] [Abstract][Full Text] [Related]
9. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
11. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
12. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
[TBL] [Abstract][Full Text] [Related]
13. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
[TBL] [Abstract][Full Text] [Related]
14.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
15. Small cell carcinoma of the prostate: an immunohistochemical study.
Yao JL; Madeb R; Bourne P; Lei J; Yang X; Tickoo S; Liu Z; Tan D; Cheng L; Hatem F; Huang J; Anthony di Sant'Agnese P
Am J Surg Pathol; 2006 Jun; 30(6):705-12. PubMed ID: 16723847
[TBL] [Abstract][Full Text] [Related]
16. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
[TBL] [Abstract][Full Text] [Related]
17. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
Aparicio AM; Shen L; Tapia EL; Lu JF; Chen HC; Zhang J; Wu G; Wang X; Troncoso P; Corn P; Thompson TC; Broom B; Baggerly K; Maity SN; Logothetis CJ
Clin Cancer Res; 2016 Mar; 22(6):1520-30. PubMed ID: 26546618
[TBL] [Abstract][Full Text] [Related]
18. A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
Jiang L; Bai Z; Zhu S; Zhao T; Yang Y; Li Z; Chen D; Wu Z; Wang Y; Zhou F; Li Y
BMC Urol; 2021 Aug; 21(1):114. PubMed ID: 34425813
[TBL] [Abstract][Full Text] [Related]
19. DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
Zhu S; Zhang Z; Zhang H; Liu Z; Liu M; Liu Q; Zang L; Wang L; Ji J; Wu B; Sun L; Zhang Z; Cao H; Wang Y; Wang H; Shang Z; Niu Y
Prostate; 2022 Mar; 82(4):464-474. PubMed ID: 35037281
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
